Drugs / TGFBeta resistant HER2/EBV-CTLs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00889954 | May 2009 → Jul 2015 | HER2 positive breast carcinoma | Baylor College of Medicine | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TGFBeta resistant HER2/EBV-CTLs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00889954 ↗ |
| Modality | Cell therapy | “EBV-specific T cells will be made.” NCT00889954 ↗ |
| Route | Intravenous | “one dose of cells into the vein through an IV line.” NCT00889954 ↗ |